Welcome to our dedicated page for QUAKER CHEMICAL SEC filings (Ticker: KWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QUAKER CHEMICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QUAKER CHEMICAL's regulatory disclosures and financial reporting.
Quaker Chemical Corp: The Vanguard Group filed an amended Schedule 13G/A reporting that it beneficially owns 0 shares of Quaker Chemical Corp common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or divisions to report beneficial ownership separately.
Quaker Chemical Corp senior vice president, general counsel and corporate secretary Robert T. Traub reported a series of equity compensation transactions on March 15, 2026.
He received 1,772 time-based restricted stock units and 1,028 shares of common stock earned from performance stock units granted in 2023, following certification of the company’s adjusted return on invested capital performance. Previously granted RSUs and dividend equivalent rights were also converted into common stock.
In connection with these vestings, 562 shares of common stock were surrendered at $118.45 per share to cover withholding taxes, a non‑market disposition. After these transactions, Traub directly holds 4,351 shares of common stock, and indirectly holds 1,262 shares through a 401(k) plan as of December 31, 2025.
Quaker Chemical’s SVP and Chief Human Resources Officer Kristin Rokosky reported routine equity compensation activity. On March 15, 2026, performance stock units and restricted stock units vested and were settled into 487 shares of common stock, with additional shares from dividend equivalent rights, and she also received a new grant of 1,350 time-based RSUs that vest in three annual installments beginning March 15, 2027. In connection with these vestings, she was awarded 80 shares of common stock and then on March 16, 2026 surrendered 177 shares at $118.45 per share to cover withholding taxes. Following these transactions, Rokosky directly holds 1,109 shares of Quaker Chemical common stock, while the newly granted RSUs represent additional contingent future equity.
Quaker Chemical senior vice president Miguel Moreno Hernandez reported routine equity compensation activity involving restricted stock units, performance stock units, and related dividend equivalents. On March 15, 2026, he received grants of 759 restricted stock units and 120 shares of common stock, both at no cash cost to him. Previously awarded restricted stock units, performance stock units, and dividend equivalent rights were exercised or settled into 363 shares of common stock. To cover withholding taxes on these vestings, 241 shares of common stock were surrendered at $118.45 per share. After all transactions, he directly holds 2,184 shares of Quaker Chemical common stock, with no remaining derivative awards shown in this filing. All movements reflect compensation vesting and tax withholding, not open-market buying or selling.
Meagher Kevin K. reported acquisition or exercise transactions in this Form 4 filing.
Quaker Chemical Corporation executive Kevin K. Meagher, VP, R&D - Advanced Solutions, received a grant of 297 Restricted Stock Units (RSUs) as equity-based compensation. Each RSU represents a contingent right to receive one share of KWR common stock, with dividend equivalent rights accruing as dividends are paid.
The time-based RSUs will vest in three annual installments beginning on March 15, 2027, aligning Mr. Meagher’s long-term incentives with shareholders. Following this grant, he holds 297 RSUs directly, all subject to future vesting conditions.
Quaker Chemical SVP Ma Jun reported equity compensation activity involving restricted stock units and common shares. On March 15, 2026, Ma Jun exercised derivative awards covering 239 units tied to common stock, including performance stock units and dividend equivalent rights, converting them into common shares at a price of $0.00 per share.
The filing also shows a grant of 759 time-based restricted stock units and an award of 120 shares of common stock as compensation, all held directly. After these transactions, Ma Jun directly owns 3,295 shares of Quaker Chemical common stock. Footnotes describe multi-year vesting schedules and that RSUs and related dividend equivalents convert one-for-one into common stock.
Quaker Chemical SVP and CTO Christine Procopio Johnson reported routine equity compensation activity involving restricted stock units (RSUs) and related common shares. On March 15, 2026, 304 RSUs and 2 dividend equivalent rights converted into 306 shares of common stock, reflecting the first installment vesting of a 2025 RSU grant.
To cover withholding taxes on this vesting, 111 shares were surrendered at a price of $118.45 per share, leaving 195 common shares held directly afterward. Johnson also received a new grant of 1,013 time-based RSUs that vest in three annual installments beginning on March 15, 2027, each representing a contingent right to one share of Quaker Chemical common stock with dividend equivalents accruing over time.
Quaker Chemical vice president Andre Frodl reported multiple equity compensation events on March 15, 2026. He exercised vested performance and restricted stock units and related dividend equivalent rights into 237 shares of Common Stock, and received a separate grant of 371 time-based RSUs under the Long-Term Performance Incentive Plan.
The filing also shows an additional 72 shares of Common Stock awarded, while 149 shares were surrendered to satisfy withholding taxes on the vesting of RSUs and PSUs. Following these transactions, Frodl directly holds 771 shares of Common Stock and 371 RSUs, which vest in three annual installments beginning on March 15, 2027.
Quaker Chemical vice president and Principal Accounting Officer Steven R. Dassing reported routine stock-based compensation activity. On March 15, 2026, previously granted performance and restricted stock units, plus dividend equivalent rights, were exercised into 302 shares of common stock at a stated price of $0.00 per share.
On the same date, he received new awards of 1,823 restricted stock units and 39 shares of common stock. To cover withholding taxes on these vestings, 130 shares were surrendered at $118.45 per share. After these transactions, he directly holds 368 shares of common stock.
Quaker Chemical EVP and CFO Thomas Coler reported routine equity compensation activity involving restricted stock units (RSUs) and related common shares. On March 15, 2026, RSUs and dividend equivalent rights converted into 1,578 shares of common stock, reflecting vesting of prior awards granted under the Long-Term Performance Incentive Plan.
To cover withholding taxes on this vesting, 541 common shares were surrendered back to the company, a non-market, tax-withholding disposition. After these transactions, Coler directly held 1,478 shares of common stock. He also received a new grant of 2,870 time-based RSUs, which will vest in three annual installments beginning March 15, 2027, each RSU representing a contingent right to one share of Quaker Chemical common stock with dividend equivalent rights accruing as dividends are paid.